id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323092-j2u0ny2u	Crosby, James C.	COVID‐19: A review of therapeutics under investigation	2020-04-19		.txt	text/plain	3896	270	51	The World Health Organization (WHO) has released general guidelines for managing the illness caused by the virus (COVID-19), which includes supportive care similar to other viral pneumonias: airway and respiratory support, empiric antibiotics for secondary bacterial infection, and acute respiratory distress syndrome (ARDS) management. 2 While these treatments are thought to offer the best chance of survival for the approximately 20% of COVID-19 cases that progress to severe disease, limited health care resources and the speed at which the pandemic has developed are pressuring clinicians and scientists to provide therapeutics that specifically target SARS-CoV-2 and improve mortality. 32, 33 There are a number of promising studies that have demonstrated shorter hospital stays, lower mortality rates, and reduced viral loads in SARS-CoV-1 and H1N1 influenza infected patients treated with convalescent plasma. There is another single ongoing observational trial examining the efficacy of anti-SARS-CoV-2 inactivated convalescent plasma in COVID-19 patients, the results of which remain to be seen.	./cache/cord-323092-j2u0ny2u.txt	./txt/cord-323092-j2u0ny2u.txt